Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
NeuroMetrix Report Highlights Stigma Faced by Chronic Pain Community around Opioid Use, Desire for Alternative Treatments | ||
By: Nasdaq / GlobeNewswire - 21 Jun 2018 | Back to overview list |
|
84 percent of Americans living with chronic pain believe there is a stigma around opioid use; 90 percent are actively seeking alternative treatments WALTHAM, Mass., June 21, 2018 (GLOBE NEWSWIRE) -- The opioid crisis continues to make headlines, but in the midst of this chaos, members of the chronic pain community are grappling with how to manage their conditions under increased scrutiny. In an effort to shed light on how the opioid epidemic is impacting the 100 million Americans living with chronic pain, NeuroMetrix today released a new report, “Flipping the Script: Living with Chronic Pain amid the Opioid Crisis.” The report takes an in-depth look at the other side of the national crisis and how the stigma of opioid use is driving patient empowerment in the search for non-prescription treatments. “The rise of the opioid epidemic has had a significant impact on those living with chronic pain, and oftentimes the voice of this population has gotten lost. We wanted to shine some light on the experiences of chronic pain sufferers with this research,” said Shai N. Gozani, Ph.D., M.D., president and CEO of NeuroMetrix. “These results underscore the need for more research and treatment modalities to support those living with chronic pain, as well as a joint effort among care providers, innovators, government stakeholders and patients to expand the goals of pain treatment. If we shift focus to making the end goal of pain treatment about decreasing suffering and disability rather than exclusively pain intensity, we may open ourselves to new possibilities and treatments that will empower those with chronic pain to find relief and gain greater control over their lives.” NeuroMetrix, a commercial stage neurostimulation and digital medicine company and creators of Quell Wearable Pain Relief Technology, partnered with Vanson Bourne to field the research, surveying 1,500 Americans (adults 25 and older) living with a wide range of chronic pain conditions. Most respondents indicated they are currently or have taken opioids for the treatment of chronic pain (62 percent). Key report findings include:
"There is no magic bullet for chronic pain, and people often have to employ multiple different therapies to achieve some relief," says Nicole Hemmenway, interim CEO of U.S. Pain Foundation. "Unfortunately, many patients find their options for relief are limited by affordability and accessibility. We need to do more to encourage insurers to provide better coverage to safe, alternative pain management approaches, like wearable devices." To access the complete report, visit https://www.quellrelief.com/flipping-the-script. Methodology About NeuroMetrix About Quell NeuroMetrix, Inc. Source: NeuroMetrix, Inc. |
||
|
||
Copyright 2018 Nasdaq / GlobeNewswire | Back to overview list |